Cargando…
LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys
Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator that represents a promising target for the treatment of several metabolic diseases. Administration of recombinant wild type FGF21 to diabetic animals leads to a dramatic improvement in glycaemia and ameliorates other systemic measure...
Autores principales: | Adams, Andrew C., Halstead, Carolyn A., Hansen, Barbara C., Irizarry, Armando R., Martin, Jennifer A., Myers, Sharon R., Reynolds, Vincent L., Smith, Holly W., Wroblewski, Victor J., Kharitonenkov, Alexei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688819/ https://www.ncbi.nlm.nih.gov/pubmed/23823755 http://dx.doi.org/10.1371/journal.pone.0065763 |
Ejemplares similares
-
Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319
por: Kharitonenkov, Alexei, et al.
Publicado: (2013) -
Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012) -
Inventing new medicines: The FGF21 story()
por: Kharitonenkov, Alexei, et al.
Publicado: (2013) -
FGF19 and FGF21: In NASH we trust
por: Talukdar, Saswata, et al.
Publicado: (2020) -
FGF21 Requires βklotho to Act In Vivo
por: Adams, Andrew C., et al.
Publicado: (2012)